aluates Reports

$ 0.0

Automative

Global Biologics for Immune Diseases and Inflammation Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-7K20253

BUY CHAPTERS

Global Biologics for Immune Diseases and Inflammation Market Research Report 2025

Code: QYRE-Auto-7K20253

Report

November 2025

Pages:136

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Biologics for Immune Diseases and Inflammation Market Size

The global market for Biologics for Immune Diseases and Inflammation was valued at US$ 123884 million in the year 2024 and is projected to reach a revised size of US$ 210411 million by 2031, growing at a CAGR of 8.1% during the forecast period.

Biologics for Immune Diseases and Inflammation Market

In the pharmaceutical field, biomanufacturing refers to the use of living biological systems (such as mammalian, microbial, or plant cells) as "production factories" to transform complex biomolecules into drugs for the treatment or prevention of diseases through precisely controlled cultivation, fermentation, isolation, and purification processes. This process differs from traditional chemical synthesis in that it emphasizes the correct folding, modification, and biological activity of macromolecules such as proteins and nucleic acids. It also requires strict adherence to regulatory standards such as cGMP to ensure product safety, efficacy, and batch consistency. Typical products include monoclonal antibodies, recombinant proteins, vaccines, and gene or cell therapy formulations, reflecting the shift in modern pharmaceutical manufacturing from chemical manufacturing to bio-driven innovation.

Immune diseases stem from an imbalance or overreaction of the immune system. Rheumatoid arthritis, inflammatory bowel disease, and psoriasis are typical examples. Biologic drugs have been game-changing in this field. For example, adalimumab, which blocks TNF-α signaling, has significantly improved the quality of life for arthritis patients. In recent years, the emergence of drugs targeting more specific targets, such as IL-17 and IL-23, has made treatment more selective and safer. The future trend is toward personalized precision medicine: identifying patient subtypes through inflammatory markers and administering the most appropriate biologic to achieve the optimal balance of efficacy and safety.

Biologics (pharmaceuticals) for immune and inflammatory diseases include monoclonal antibodies, antibody-drug conjugates (ADCs), and recombinant protein drugs. Representative drugs include STELARA (2024 sales of US$10,361 million), Humira (2024 sales of US$8,993 million), Cosentyx (2024 sales of US$6,141 million), and Orencia (2024 sales of US$3,682 million). The gross profit margin is above 70%.

In recent years, the pharmaceutical industry's R&D focus has shifted from solely focusing on the discovery and optimization of small molecule drugs. Driven by biomanufacturing, the product portfolio has evolved into a multimodal, biology-centric landscape. While traditional proteins and monoclonal antibodies remain the bulk of the market, manufacturing processes are constantly being optimized to improve yield and quality consistency. Meanwhile, emerging therapeutic modalities such as cell and gene therapies, mRNA, nucleic acid therapies, and gene editing-related products are placing new demands on biomanufacturing. Upstream cell line development, expression system optimization, vector production, sterile and pyrogen-free downstream purification, and process stability for both in vitro and in vivo delivery systems have all become key R&D priorities. Consequently, the boundaries between R&D and manufacturing are becoming increasingly blurred: early-stage molecular design must consider manufacturability for scalable production, while process development, in turn, influences clinical dosing regimens and development cadence. With the maturity of AI/data-driven design, synthetic biology, and high-throughput screening technologies, the path from early target identification to producible biologics has been significantly shortened. This, in turn, requires manufacturing teams to engage earlier in early drug development to ensure that candidate molecules do not encounter unresolvable process bottlenecks when entering mid- to late-stage large-scale production. As a result, R&D trends are clearly shifting from single-molecule innovation to molecule-process co-design. This trend will continue to intensify, driving companies to adjust their R&D organizational structures and investment allocations to balance scientific innovation with production feasibility.

Autoimmune diseases occur when the immune system attacks the body. The immune system protects the body by distinguishing between pathogens, cancer cells, and normal cells. Sometimes, the immune system mistakenly identifies healthy cells as foreign and produces antibodies to attack and destroy them. Some autoimmune diseases can be treated with biologics. Biologics, also known as biological response modifiers, are substances produced by living organisms that modulate immune responses. Some of the most common diseases treated with biologic autoimmune therapies include psoriasis, multiple sclerosis, ankylosing spondylitis, and rheumatoid arthritis (RA). Biologics are one of the newer autoimmune therapies. These targeted drugs are genetically engineered to block overactive parts of the immune system, preventing the body from attacking itself. Tumor necrosis factor (TNF) blockers, interleukin (IL) antagonists, and B and T cell inhibitors are the main types of biologics. These treatments are ideal for patients whose symptoms are severe and have not responded to other treatments.

This report aims to provide a comprehensive presentation of the global market for Biologics for Immune Diseases and Inflammation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics for Immune Diseases and Inflammation.

The Biologics for Immune Diseases and Inflammation market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biologics for Immune Diseases and Inflammation market comprehensively. Regional market sizes, concerning products by Type, by Application, by Properties and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biologics for Immune Diseases and Inflammation companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Biologics for Immune Diseases and Inflammation Market Report

Report Metric	Details
Report Name	Biologics for Immune Diseases and Inflammation Market
Accounted market size in year	US$ 123884 million
Forecasted market size in 2031	US$ 210411 million
CAGR	8.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Antibody Drugs Recombinant Protein Drugs Blood Products CAR-T Drugs Small Nucleic Acid Drugs Others
Segment by Properties	Biopharmaceuticals Biosimilars
Segment by Application	Autoimmune Diseases Autoinflammatory Diseases Allergic Diseases Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Merck, Novo Nordisk, Sanofi, Johnson & Johnson, AbbVie, Amgen, AstraZeneca, Takeda Pharmaceuticals, Bristol-Myers Squib, Pfizer, Eli Lilly, Novartis, GSK, CSL Limited, Regeneron Pharmaceuticals, Kexing Biopharm, Biogen, GileadSciences, Shanghai Junshi Biosciences, Sarepta Therapeutics, Inc., Changchun High-Tech Industry, Sino Biopharmaceutical Limited, Bio-Thera Solutions, 3SBio Inc., CARsgen, Innovent Biologics, Qilu Pharmaceutical, Boehringer Ingelheim, BeiGene, Jiangsu Hengrui Pharmaceuticals, Alphamab Oncology, Shanghai Henlius Biotech, Ionis Pharmaceuticals, Gan & Lee Pharmaceuticals, Anhui Anke Biotechnology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Properties etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics for Immune Diseases and Inflammation company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Biologics for Immune Diseases and Inflammation Market growing?

Ans: The Biologics for Immune Diseases and Inflammation Market witnessing a CAGR of 8.1% during the forecast period 2025-2031.

What is the Biologics for Immune Diseases and Inflammation Market size in 2031?

Ans: The Biologics for Immune Diseases and Inflammation Market size in 2031 will be US$ 210411 million.

Who are the main players in the Biologics for Immune Diseases and Inflammation Market report?

Ans: The main players in the Biologics for Immune Diseases and Inflammation Market are Roche, Merck, Novo Nordisk, Sanofi, Johnson & Johnson, AbbVie, Amgen, AstraZeneca, Takeda Pharmaceuticals, Bristol-Myers Squib, Pfizer, Eli Lilly, Novartis, GSK, CSL Limited, Regeneron Pharmaceuticals, Kexing Biopharm, Biogen, GileadSciences, Shanghai Junshi Biosciences, Sarepta Therapeutics, Inc., Changchun High-Tech Industry, Sino Biopharmaceutical Limited, Bio-Thera Solutions, 3SBio Inc., CARsgen, Innovent Biologics, Qilu Pharmaceutical, Boehringer Ingelheim, BeiGene, Jiangsu Hengrui Pharmaceuticals, Alphamab Oncology, Shanghai Henlius Biotech, Ionis Pharmaceuticals, Gan & Lee Pharmaceuticals, Anhui Anke Biotechnology

What are the Application segmentation covered in the Biologics for Immune Diseases and Inflammation Market report?

Ans: The Applications covered in the Biologics for Immune Diseases and Inflammation Market report are Autoimmune Diseases, Autoinflammatory Diseases, Allergic Diseases, Others

What are the Type segmentation covered in the Biologics for Immune Diseases and Inflammation Market report?

Ans: The Types covered in the Biologics for Immune Diseases and Inflammation Market report are Antibody Drugs, Recombinant Protein Drugs, Blood Products, CAR-T Drugs, Small Nucleic Acid Drugs, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antibody Drugs

1.2.3 Recombinant Protein Drugs

1.2.4 Blood Products

1.2.5 CAR-T Drugs

1.2.6 Small Nucleic Acid Drugs

1.2.7 Others

1.3 Market by Properties

1.3.1 Global Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Properties: 2020 VS 2024 VS 2031

1.3.2 Biopharmaceuticals

1.3.3 Biosimilars

1.4 Market by Application

1.4.1 Global Biologics for Immune Diseases and Inflammation Market Growth by Application: 2020 VS 2024 VS 2031

1.4.2 Autoimmune Diseases

1.4.3 Autoinflammatory Diseases

1.4.4 Allergic Diseases

1.4.5 Others

1.5 Assumptions and Limitations

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Global Biologics for Immune Diseases and Inflammation Market Perspective (2020-2031)

2.2 Global Biologics for Immune Diseases and Inflammation Growth Trends by Region

2.2.1 Global Biologics for Immune Diseases and Inflammation Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Biologics for Immune Diseases and Inflammation Historic Market Size by Region (2020-2025)

2.2.3 Biologics for Immune Diseases and Inflammation Forecasted Market Size by Region (2026-2031)

2.3 Biologics for Immune Diseases and Inflammation Market Dynamics

2.3.1 Biologics for Immune Diseases and Inflammation Industry Trends

2.3.2 Biologics for Immune Diseases and Inflammation Market Drivers

2.3.3 Biologics for Immune Diseases and Inflammation Market Challenges

2.3.4 Biologics for Immune Diseases and Inflammation Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Biologics for Immune Diseases and Inflammation Players by Revenue

3.1.1 Global Top Biologics for Immune Diseases and Inflammation Players by Revenue (2020-2025)

3.1.2 Global Biologics for Immune Diseases and Inflammation Revenue Market Share by Players (2020-2025)

3.2 Global Top Biologics for Immune Diseases and Inflammation Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Biologics for Immune Diseases and Inflammation Revenue

3.4 Global Biologics for Immune Diseases and Inflammation Market Concentration Ratio

3.4.1 Global Biologics for Immune Diseases and Inflammation Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Biologics for Immune Diseases and Inflammation Revenue in 2024

3.5 Global Key Players of Biologics for Immune Diseases and Inflammation Head office and Area Served

3.6 Global Key Players of Biologics for Immune Diseases and Inflammation, Product and Application

3.7 Global Key Players of Biologics for Immune Diseases and Inflammation, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Biologics for Immune Diseases and Inflammation Breakdown Data by Type

4.1 Global Biologics for Immune Diseases and Inflammation Historic Market Size by Type (2020-2025)

4.2 Global Biologics for Immune Diseases and Inflammation Forecasted Market Size by Type (2026-2031)

5 Biologics for Immune Diseases and Inflammation Breakdown Data by Application

5.1 Global Biologics for Immune Diseases and Inflammation Historic Market Size by Application (2020-2025)

5.2 Global Biologics for Immune Diseases and Inflammation Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Biologics for Immune Diseases and Inflammation Market Size (2020-2031)

6.2 North America Biologics for Immune Diseases and Inflammation Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025)

6.4 North America Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Biologics for Immune Diseases and Inflammation Market Size (2020-2031)

7.2 Europe Biologics for Immune Diseases and Inflammation Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025)

7.4 Europe Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Biologics for Immune Diseases and Inflammation Market Size (2020-2031)

8.2 Asia-Pacific Biologics for Immune Diseases and Inflammation Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Biologics for Immune Diseases and Inflammation Market Size by Region (2020-2025)

8.4 Asia-Pacific Biologics for Immune Diseases and Inflammation Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Biologics for Immune Diseases and Inflammation Market Size (2020-2031)

9.2 Latin America Biologics for Immune Diseases and Inflammation Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025)

9.4 Latin America Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Biologics for Immune Diseases and Inflammation Market Size (2020-2031)

10.2 Middle East & Africa Biologics for Immune Diseases and Inflammation Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025)

10.4 Middle East & Africa Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Biologics for Immune Diseases and Inflammation Introduction

11.1.4 Roche Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.1.5 Roche Recent Development

11.2 Merck

11.2.1 Merck Company Details

11.2.2 Merck Business Overview

11.2.3 Merck Biologics for Immune Diseases and Inflammation Introduction

11.2.4 Merck Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.2.5 Merck Recent Development

11.3 Novo Nordisk

11.3.1 Novo Nordisk Company Details

11.3.2 Novo Nordisk Business Overview

11.3.3 Novo Nordisk Biologics for Immune Diseases and Inflammation Introduction

11.3.4 Novo Nordisk Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.3.5 Novo Nordisk Recent Development

11.4 Sanofi

11.4.1 Sanofi Company Details

11.4.2 Sanofi Business Overview

11.4.3 Sanofi Biologics for Immune Diseases and Inflammation Introduction

11.4.4 Sanofi Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.4.5 Sanofi Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Details

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Biologics for Immune Diseases and Inflammation Introduction

11.5.4 Johnson & Johnson Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.5.5 Johnson & Johnson Recent Development

11.6 AbbVie

11.6.1 AbbVie Company Details

11.6.2 AbbVie Business Overview

11.6.3 AbbVie Biologics for Immune Diseases and Inflammation Introduction

11.6.4 AbbVie Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.6.5 AbbVie Recent Development

11.7 Amgen

11.7.1 Amgen Company Details

11.7.2 Amgen Business Overview

11.7.3 Amgen Biologics for Immune Diseases and Inflammation Introduction

11.7.4 Amgen Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.7.5 Amgen Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Biologics for Immune Diseases and Inflammation Introduction

11.8.4 AstraZeneca Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.8.5 AstraZeneca Recent Development

11.9 Takeda Pharmaceuticals

11.9.1 Takeda Pharmaceuticals Company Details

11.9.2 Takeda Pharmaceuticals Business Overview

11.9.3 Takeda Pharmaceuticals Biologics for Immune Diseases and Inflammation Introduction

11.9.4 Takeda Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.9.5 Takeda Pharmaceuticals Recent Development

11.10 Bristol-Myers Squib

11.10.1 Bristol-Myers Squib Company Details

11.10.2 Bristol-Myers Squib Business Overview

11.10.3 Bristol-Myers Squib Biologics for Immune Diseases and Inflammation Introduction

11.10.4 Bristol-Myers Squib Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.10.5 Bristol-Myers Squib Recent Development

11.11 Pfizer

11.11.1 Pfizer Company Details

11.11.2 Pfizer Business Overview

11.11.3 Pfizer Biologics for Immune Diseases and Inflammation Introduction

11.11.4 Pfizer Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.11.5 Pfizer Recent Development

11.12 Eli Lilly

11.12.1 Eli Lilly Company Details

11.12.2 Eli Lilly Business Overview

11.12.3 Eli Lilly Biologics for Immune Diseases and Inflammation Introduction

11.12.4 Eli Lilly Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.12.5 Eli Lilly Recent Development

11.13 Novartis

11.13.1 Novartis Company Details

11.13.2 Novartis Business Overview

11.13.3 Novartis Biologics for Immune Diseases and Inflammation Introduction

11.13.4 Novartis Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.13.5 Novartis Recent Development

11.14 GSK

11.14.1 GSK Company Details

11.14.2 GSK Business Overview

11.14.3 GSK Biologics for Immune Diseases and Inflammation Introduction

11.14.4 GSK Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.14.5 GSK Recent Development

11.15 CSL Limited

11.15.1 CSL Limited Company Details

11.15.2 CSL Limited Business Overview

11.15.3 CSL Limited Biologics for Immune Diseases and Inflammation Introduction

11.15.4 CSL Limited Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.15.5 CSL Limited Recent Development

11.16 Regeneron Pharmaceuticals

11.16.1 Regeneron Pharmaceuticals Company Details

11.16.2 Regeneron Pharmaceuticals Business Overview

11.16.3 Regeneron Pharmaceuticals Biologics for Immune Diseases and Inflammation Introduction

11.16.4 Regeneron Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.16.5 Regeneron Pharmaceuticals Recent Development

11.17 Kexing Biopharm

11.17.1 Kexing Biopharm Company Details

11.17.2 Kexing Biopharm Business Overview

11.17.3 Kexing Biopharm Biologics for Immune Diseases and Inflammation Introduction

11.17.4 Kexing Biopharm Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.17.5 Kexing Biopharm Recent Development

11.18 Biogen

11.18.1 Biogen Company Details

11.18.2 Biogen Business Overview

11.18.3 Biogen Biologics for Immune Diseases and Inflammation Introduction

11.18.4 Biogen Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.18.5 Biogen Recent Development

11.19 GileadSciences

11.19.1 GileadSciences Company Details

11.19.2 GileadSciences Business Overview

11.19.3 GileadSciences Biologics for Immune Diseases and Inflammation Introduction

11.19.4 GileadSciences Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.19.5 GileadSciences Recent Development

11.20 Shanghai Junshi Biosciences

11.20.1 Shanghai Junshi Biosciences Company Details

11.20.2 Shanghai Junshi Biosciences Business Overview

11.20.3 Shanghai Junshi Biosciences Biologics for Immune Diseases and Inflammation Introduction

11.20.4 Shanghai Junshi Biosciences Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.20.5 Shanghai Junshi Biosciences Recent Development

11.21 Sarepta Therapeutics, Inc.

11.21.1 Sarepta Therapeutics, Inc. Company Details

11.21.2 Sarepta Therapeutics, Inc. Business Overview

11.21.3 Sarepta Therapeutics, Inc. Biologics for Immune Diseases and Inflammation Introduction

11.21.4 Sarepta Therapeutics, Inc. Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.21.5 Sarepta Therapeutics, Inc. Recent Development

11.22 Changchun High-Tech Industry

11.22.1 Changchun High-Tech Industry Company Details

11.22.2 Changchun High-Tech Industry Business Overview

11.22.3 Changchun High-Tech Industry Biologics for Immune Diseases and Inflammation Introduction

11.22.4 Changchun High-Tech Industry Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.22.5 Changchun High-Tech Industry Recent Development

11.23 Sino Biopharmaceutical Limited

11.23.1 Sino Biopharmaceutical Limited Company Details

11.23.2 Sino Biopharmaceutical Limited Business Overview

11.23.3 Sino Biopharmaceutical Limited Biologics for Immune Diseases and Inflammation Introduction

11.23.4 Sino Biopharmaceutical Limited Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.23.5 Sino Biopharmaceutical Limited Recent Development

11.24 Bio-Thera Solutions

11.24.1 Bio-Thera Solutions Company Details

11.24.2 Bio-Thera Solutions Business Overview

11.24.3 Bio-Thera Solutions Biologics for Immune Diseases and Inflammation Introduction

11.24.4 Bio-Thera Solutions Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.24.5 Bio-Thera Solutions Recent Development

11.25 3SBio Inc.

11.25.1 3SBio Inc. Company Details

11.25.2 3SBio Inc. Business Overview

11.25.3 3SBio Inc. Biologics for Immune Diseases and Inflammation Introduction

11.25.4 3SBio Inc. Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.25.5 3SBio Inc. Recent Development

11.26 CARsgen

11.26.1 CARsgen Company Details

11.26.2 CARsgen Business Overview

11.26.3 CARsgen Biologics for Immune Diseases and Inflammation Introduction

11.26.4 CARsgen Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.26.5 CARsgen Recent Development

11.27 Innovent Biologics

11.27.1 Innovent Biologics Company Details

11.27.2 Innovent Biologics Business Overview

11.27.3 Innovent Biologics Biologics for Immune Diseases and Inflammation Introduction

11.27.4 Innovent Biologics Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.27.5 Innovent Biologics Recent Development

11.28 Qilu Pharmaceutical

11.28.1 Qilu Pharmaceutical Company Details

11.28.2 Qilu Pharmaceutical Business Overview

11.28.3 Qilu Pharmaceutical Biologics for Immune Diseases and Inflammation Introduction

11.28.4 Qilu Pharmaceutical Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.28.5 Qilu Pharmaceutical Recent Development

11.29 Boehringer Ingelheim

11.29.1 Boehringer Ingelheim Company Details

11.29.2 Boehringer Ingelheim Business Overview

11.29.3 Boehringer Ingelheim Biologics for Immune Diseases and Inflammation Introduction

11.29.4 Boehringer Ingelheim Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.29.5 Boehringer Ingelheim Recent Development

11.30 BeiGene

11.30.1 BeiGene Company Details

11.30.2 BeiGene Business Overview

11.30.3 BeiGene Biologics for Immune Diseases and Inflammation Introduction

11.30.4 BeiGene Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.30.5 BeiGene Recent Development

11.31 Jiangsu Hengrui Pharmaceuticals

11.31.1 Jiangsu Hengrui Pharmaceuticals Company Details

11.31.2 Jiangsu Hengrui Pharmaceuticals Business Overview

11.31.3 Jiangsu Hengrui Pharmaceuticals Biologics for Immune Diseases and Inflammation Introduction

11.31.4 Jiangsu Hengrui Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.31.5 Jiangsu Hengrui Pharmaceuticals Recent Development

11.32 Alphamab Oncology

11.32.1 Alphamab Oncology Company Details

11.32.2 Alphamab Oncology Business Overview

11.32.3 Alphamab Oncology Biologics for Immune Diseases and Inflammation Introduction

11.32.4 Alphamab Oncology Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.32.5 Alphamab Oncology Recent Development

11.33 Shanghai Henlius Biotech

11.33.1 Shanghai Henlius Biotech Company Details

11.33.2 Shanghai Henlius Biotech Business Overview

11.33.3 Shanghai Henlius Biotech Biologics for Immune Diseases and Inflammation Introduction

11.33.4 Shanghai Henlius Biotech Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.33.5 Shanghai Henlius Biotech Recent Development

11.34 Ionis Pharmaceuticals

11.34.1 Ionis Pharmaceuticals Company Details

11.34.2 Ionis Pharmaceuticals Business Overview

11.34.3 Ionis Pharmaceuticals Biologics for Immune Diseases and Inflammation Introduction

11.34.4 Ionis Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.34.5 Ionis Pharmaceuticals Recent Development

11.35 Gan & Lee Pharmaceuticals

11.35.1 Gan & Lee Pharmaceuticals Company Details

11.35.2 Gan & Lee Pharmaceuticals Business Overview

11.35.3 Gan & Lee Pharmaceuticals Biologics for Immune Diseases and Inflammation Introduction

11.35.4 Gan & Lee Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.35.5 Gan & Lee Pharmaceuticals Recent Development

11.36 Anhui Anke Biotechnology

11.36.1 Anhui Anke Biotechnology Company Details

11.36.2 Anhui Anke Biotechnology Business Overview

11.36.3 Anhui Anke Biotechnology Biologics for Immune Diseases and Inflammation Introduction

11.36.4 Anhui Anke Biotechnology Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025)

11.36.5 Anhui Anke Biotechnology Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antibody Drugs

Table 3. Key Players of Recombinant Protein Drugs

Table 4. Key Players of Blood Products

Table 5. Key Players of CAR-T Drugs

Table 6. Key Players of Small Nucleic Acid Drugs

Table 7. Key Players of Others

Table 8. Global Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Properties (US$ Million): 2020 VS 2024 VS 2031

Table 9. Key Players of Biopharmaceuticals

Table 10. Key Players of Biosimilars

Table 11. Global Biologics for Immune Diseases and Inflammation Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 12. Global Biologics for Immune Diseases and Inflammation Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 13. Global Biologics for Immune Diseases and Inflammation Market Size by Region (2020-2025) & (US$ Million)

Table 14. Global Biologics for Immune Diseases and Inflammation Market Share by Region (2020-2025)

Table 15. Global Biologics for Immune Diseases and Inflammation Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 16. Global Biologics for Immune Diseases and Inflammation Market Share by Region (2026-2031)

Table 17. Biologics for Immune Diseases and Inflammation Market Trends

Table 18. Biologics for Immune Diseases and Inflammation Market Drivers

Table 19. Biologics for Immune Diseases and Inflammation Market Challenges

Table 20. Biologics for Immune Diseases and Inflammation Market Restraints

Table 21. Global Biologics for Immune Diseases and Inflammation Revenue by Players (2020-2025) & (US$ Million)

Table 22. Global Biologics for Immune Diseases and Inflammation Market Share by Players (2020-2025)

Table 23. Global Top Biologics for Immune Diseases and Inflammation Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics for Immune Diseases and Inflammation as of 2024)

Table 24. Ranking of Global Top Biologics for Immune Diseases and Inflammation Companies by Revenue (US$ Million) in 2024

Table 25. Global 5 Largest Players Market Share by Biologics for Immune Diseases and Inflammation Revenue (CR5 and HHI) & (2020-2025)

Table 26. Global Key Players of Biologics for Immune Diseases and Inflammation, Headquarters and Area Served

Table 27. Global Key Players of Biologics for Immune Diseases and Inflammation, Product and Application

Table 28. Global Key Players of Biologics for Immune Diseases and Inflammation, Date of Enter into This Industry

Table 29. Mergers & Acquisitions, Expansion Plans

Table 30. Global Biologics for Immune Diseases and Inflammation Market Size by Type (2020-2025) & (US$ Million)

Table 31. Global Biologics for Immune Diseases and Inflammation Revenue Market Share by Type (2020-2025)

Table 32. Global Biologics for Immune Diseases and Inflammation Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 33. Global Biologics for Immune Diseases and Inflammation Revenue Market Share by Type (2026-2031)

Table 34. Global Biologics for Immune Diseases and Inflammation Market Size by Application (2020-2025) & (US$ Million)

Table 35. Global Biologics for Immune Diseases and Inflammation Revenue Market Share by Application (2020-2025)

Table 36. Global Biologics for Immune Diseases and Inflammation Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 37. Global Biologics for Immune Diseases and Inflammation Revenue Market Share by Application (2026-2031)

Table 38. North America Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. North America Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025) & (US$ Million)

Table 40. North America Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031) & (US$ Million)

Table 41. Europe Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Europe Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025) & (US$ Million)

Table 43. Europe Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031) & (US$ Million)

Table 44. Asia-Pacific Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 45. Asia-Pacific Biologics for Immune Diseases and Inflammation Market Size by Region (2020-2025) & (US$ Million)

Table 46. Asia-Pacific Biologics for Immune Diseases and Inflammation Market Size by Region (2026-2031) & (US$ Million)

Table 47. Latin America Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Latin America Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025) & (US$ Million)

Table 49. Latin America Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031) & (US$ Million)

Table 50. Middle East & Africa Biologics for Immune Diseases and Inflammation Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 51. Middle East & Africa Biologics for Immune Diseases and Inflammation Market Size by Country (2020-2025) & (US$ Million)

Table 52. Middle East & Africa Biologics for Immune Diseases and Inflammation Market Size by Country (2026-2031) & (US$ Million)

Table 53. Roche Company Details

Table 54. Roche Business Overview

Table 55. Roche Biologics for Immune Diseases and Inflammation Product

Table 56. Roche Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 57. Roche Recent Development

Table 58. Merck Company Details

Table 59. Merck Business Overview

Table 60. Merck Biologics for Immune Diseases and Inflammation Product

Table 61. Merck Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 62. Merck Recent Development

Table 63. Novo Nordisk Company Details

Table 64. Novo Nordisk Business Overview

Table 65. Novo Nordisk Biologics for Immune Diseases and Inflammation Product

Table 66. Novo Nordisk Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 67. Novo Nordisk Recent Development

Table 68. Sanofi Company Details

Table 69. Sanofi Business Overview

Table 70. Sanofi Biologics for Immune Diseases and Inflammation Product

Table 71. Sanofi Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 72. Sanofi Recent Development

Table 73. Johnson & Johnson Company Details

Table 74. Johnson & Johnson Business Overview

Table 75. Johnson & Johnson Biologics for Immune Diseases and Inflammation Product

Table 76. Johnson & Johnson Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 77. Johnson & Johnson Recent Development

Table 78. AbbVie Company Details

Table 79. AbbVie Business Overview

Table 80. AbbVie Biologics for Immune Diseases and Inflammation Product

Table 81. AbbVie Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 82. AbbVie Recent Development

Table 83. Amgen Company Details

Table 84. Amgen Business Overview

Table 85. Amgen Biologics for Immune Diseases and Inflammation Product

Table 86. Amgen Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 87. Amgen Recent Development

Table 88. AstraZeneca Company Details

Table 89. AstraZeneca Business Overview

Table 90. AstraZeneca Biologics for Immune Diseases and Inflammation Product

Table 91. AstraZeneca Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 92. AstraZeneca Recent Development

Table 93. Takeda Pharmaceuticals Company Details

Table 94. Takeda Pharmaceuticals Business Overview

Table 95. Takeda Pharmaceuticals Biologics for Immune Diseases and Inflammation Product

Table 96. Takeda Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 97. Takeda Pharmaceuticals Recent Development

Table 98. Bristol-Myers Squib Company Details

Table 99. Bristol-Myers Squib Business Overview

Table 100. Bristol-Myers Squib Biologics for Immune Diseases and Inflammation Product

Table 101. Bristol-Myers Squib Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 102. Bristol-Myers Squib Recent Development

Table 103. Pfizer Company Details

Table 104. Pfizer Business Overview

Table 105. Pfizer Biologics for Immune Diseases and Inflammation Product

Table 106. Pfizer Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 107. Pfizer Recent Development

Table 108. Eli Lilly Company Details

Table 109. Eli Lilly Business Overview

Table 110. Eli Lilly Biologics for Immune Diseases and Inflammation Product

Table 111. Eli Lilly Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 112. Eli Lilly Recent Development

Table 113. Novartis Company Details

Table 114. Novartis Business Overview

Table 115. Novartis Biologics for Immune Diseases and Inflammation Product

Table 116. Novartis Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 117. Novartis Recent Development

Table 118. GSK Company Details

Table 119. GSK Business Overview

Table 120. GSK Biologics for Immune Diseases and Inflammation Product

Table 121. GSK Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 122. GSK Recent Development

Table 123. CSL Limited Company Details

Table 124. CSL Limited Business Overview

Table 125. CSL Limited Biologics for Immune Diseases and Inflammation Product

Table 126. CSL Limited Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 127. CSL Limited Recent Development

Table 128. Regeneron Pharmaceuticals Company Details

Table 129. Regeneron Pharmaceuticals Business Overview

Table 130. Regeneron Pharmaceuticals Biologics for Immune Diseases and Inflammation Product

Table 131. Regeneron Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 132. Regeneron Pharmaceuticals Recent Development

Table 133. Kexing Biopharm Company Details

Table 134. Kexing Biopharm Business Overview

Table 135. Kexing Biopharm Biologics for Immune Diseases and Inflammation Product

Table 136. Kexing Biopharm Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 137. Kexing Biopharm Recent Development

Table 138. Biogen Company Details

Table 139. Biogen Business Overview

Table 140. Biogen Biologics for Immune Diseases and Inflammation Product

Table 141. Biogen Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 142. Biogen Recent Development

Table 143. GileadSciences Company Details

Table 144. GileadSciences Business Overview

Table 145. GileadSciences Biologics for Immune Diseases and Inflammation Product

Table 146. GileadSciences Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 147. GileadSciences Recent Development

Table 148. Shanghai Junshi Biosciences Company Details

Table 149. Shanghai Junshi Biosciences Business Overview

Table 150. Shanghai Junshi Biosciences Biologics for Immune Diseases and Inflammation Product

Table 151. Shanghai Junshi Biosciences Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 152. Shanghai Junshi Biosciences Recent Development

Table 153. Sarepta Therapeutics, Inc. Company Details

Table 154. Sarepta Therapeutics, Inc. Business Overview

Table 155. Sarepta Therapeutics, Inc. Biologics for Immune Diseases and Inflammation Product

Table 156. Sarepta Therapeutics, Inc. Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 157. Sarepta Therapeutics, Inc. Recent Development

Table 158. Changchun High-Tech Industry Company Details

Table 159. Changchun High-Tech Industry Business Overview

Table 160. Changchun High-Tech Industry Biologics for Immune Diseases and Inflammation Product

Table 161. Changchun High-Tech Industry Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 162. Changchun High-Tech Industry Recent Development

Table 163. Sino Biopharmaceutical Limited Company Details

Table 164. Sino Biopharmaceutical Limited Business Overview

Table 165. Sino Biopharmaceutical Limited Biologics for Immune Diseases and Inflammation Product

Table 166. Sino Biopharmaceutical Limited Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 167. Sino Biopharmaceutical Limited Recent Development

Table 168. Bio-Thera Solutions Company Details

Table 169. Bio-Thera Solutions Business Overview

Table 170. Bio-Thera Solutions Biologics for Immune Diseases and Inflammation Product

Table 171. Bio-Thera Solutions Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 172. Bio-Thera Solutions Recent Development

Table 173. 3SBio Inc. Company Details

Table 174. 3SBio Inc. Business Overview

Table 175. 3SBio Inc. Biologics for Immune Diseases and Inflammation Product

Table 176. 3SBio Inc. Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 177. 3SBio Inc. Recent Development

Table 178. CARsgen Company Details

Table 179. CARsgen Business Overview

Table 180. CARsgen Biologics for Immune Diseases and Inflammation Product

Table 181. CARsgen Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 182. CARsgen Recent Development

Table 183. Innovent Biologics Company Details

Table 184. Innovent Biologics Business Overview

Table 185. Innovent Biologics Biologics for Immune Diseases and Inflammation Product

Table 186. Innovent Biologics Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 187. Innovent Biologics Recent Development

Table 188. Qilu Pharmaceutical Company Details

Table 189. Qilu Pharmaceutical Business Overview

Table 190. Qilu Pharmaceutical Biologics for Immune Diseases and Inflammation Product

Table 191. Qilu Pharmaceutical Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 192. Qilu Pharmaceutical Recent Development

Table 193. Boehringer Ingelheim Company Details

Table 194. Boehringer Ingelheim Business Overview

Table 195. Boehringer Ingelheim Biologics for Immune Diseases and Inflammation Product

Table 196. Boehringer Ingelheim Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 197. Boehringer Ingelheim Recent Development

Table 198. BeiGene Company Details

Table 199. BeiGene Business Overview

Table 200. BeiGene Biologics for Immune Diseases and Inflammation Product

Table 201. BeiGene Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 202. BeiGene Recent Development

Table 203. Jiangsu Hengrui Pharmaceuticals Company Details

Table 204. Jiangsu Hengrui Pharmaceuticals Business Overview

Table 205. Jiangsu Hengrui Pharmaceuticals Biologics for Immune Diseases and Inflammation Product

Table 206. Jiangsu Hengrui Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 207. Jiangsu Hengrui Pharmaceuticals Recent Development

Table 208. Alphamab Oncology Company Details

Table 209. Alphamab Oncology Business Overview

Table 210. Alphamab Oncology Biologics for Immune Diseases and Inflammation Product

Table 211. Alphamab Oncology Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 212. Alphamab Oncology Recent Development

Table 213. Shanghai Henlius Biotech Company Details

Table 214. Shanghai Henlius Biotech Business Overview

Table 215. Shanghai Henlius Biotech Biologics for Immune Diseases and Inflammation Product

Table 216. Shanghai Henlius Biotech Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 217. Shanghai Henlius Biotech Recent Development

Table 218. Ionis Pharmaceuticals Company Details

Table 219. Ionis Pharmaceuticals Business Overview

Table 220. Ionis Pharmaceuticals Biologics for Immune Diseases and Inflammation Product

Table 221. Ionis Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 222. Ionis Pharmaceuticals Recent Development

Table 223. Gan & Lee Pharmaceuticals Company Details

Table 224. Gan & Lee Pharmaceuticals Business Overview

Table 225. Gan & Lee Pharmaceuticals Biologics for Immune Diseases and Inflammation Product

Table 226. Gan & Lee Pharmaceuticals Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 227. Gan & Lee Pharmaceuticals Recent Development

Table 228. Anhui Anke Biotechnology Company Details

Table 229. Anhui Anke Biotechnology Business Overview

Table 230. Anhui Anke Biotechnology Biologics for Immune Diseases and Inflammation Product

Table 231. Anhui Anke Biotechnology Revenue in Biologics for Immune Diseases and Inflammation Business (2020-2025) & (US$ Million)

Table 232. Anhui Anke Biotechnology Recent Development

Table 233. Research Programs/Design for This Report

Table 234. Key Data Information from Secondary Sources

Table 235. Key Data Information from Primary Sources

Table 236. Authors List of This Report

List of Figures

Figure 1. Biologics for Immune Diseases and Inflammation Picture

Figure 2. Global Biologics for Immune Diseases and Inflammation Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Biologics for Immune Diseases and Inflammation Market Share by Type: 2024 VS 2031

Figure 4. Antibody Drugs Features

Figure 5. Recombinant Protein Drugs Features

Figure 6. Blood Products Features

Figure 7. CAR-T Drugs Features

Figure 8. Small Nucleic Acid Drugs Features

Figure 9. Others Features

Figure 10. Global Biologics for Immune Diseases and Inflammation Market Size Comparison by Properties (2020-2031) & (US$ Million)

Figure 11. Biopharmaceuticals Features

Figure 12. Biosimilars Features

Figure 13. Global Biologics for Immune Diseases and Inflammation Market Size by Application (2020-2031) & (US$ Million)

Figure 14. Global Biologics for Immune Diseases and Inflammation Market Share by Application: 2024 VS 2031

Figure 15. Autoimmune Diseases Case Studies

Figure 16. Autoinflammatory Diseases Case Studies

Figure 17. Allergic Diseases Case Studies

Figure 18. Others Case Studies

Figure 19. Biologics for Immune Diseases and Inflammation Report Years Considered

Figure 20. Global Biologics for Immune Diseases and Inflammation Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 21. Global Biologics for Immune Diseases and Inflammation Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 22. Global Biologics for Immune Diseases and Inflammation Market Share by Region: 2024 VS 2031

Figure 23. Global Biologics for Immune Diseases and Inflammation Market Share by Players in 2024

Figure 24. Global Biologics for Immune Diseases and Inflammation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 25. The Top 10 and 5 Players Market Share by Biologics for Immune Diseases and Inflammation Revenue in 2024

Figure 26. North America Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. North America Biologics for Immune Diseases and Inflammation Market Share by Country (2020-2031)

Figure 28. United States Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Canada Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Europe Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Europe Biologics for Immune Diseases and Inflammation Market Share by Country (2020-2031)

Figure 32. Germany Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. France Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. U.K. Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Italy Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Russia Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Ireland Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Asia-Pacific Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Asia-Pacific Biologics for Immune Diseases and Inflammation Market Share by Region (2020-2031)

Figure 40. China Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Japan Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. South Korea Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Southeast Asia Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. India Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Australia & New Zealand Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Latin America Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Latin America Biologics for Immune Diseases and Inflammation Market Share by Country (2020-2031)

Figure 48. Mexico Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Brazil Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Middle East & Africa Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Middle East & Africa Biologics for Immune Diseases and Inflammation Market Share by Country (2020-2031)

Figure 52. Israel Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. UAE Biologics for Immune Diseases and Inflammation Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. Roche Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 56. Merck Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 57. Novo Nordisk Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 58. Sanofi Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 59. Johnson & Johnson Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 60. AbbVie Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 61. Amgen Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 62. AstraZeneca Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 63. Takeda Pharmaceuticals Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 64. Bristol-Myers Squib Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 65. Pfizer Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 66. Eli Lilly Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 67. Novartis Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 68. GSK Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 69. CSL Limited Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 70. Regeneron Pharmaceuticals Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 71. Kexing Biopharm Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 72. Biogen Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 73. GileadSciences Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 74. Shanghai Junshi Biosciences Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 75. Sarepta Therapeutics, Inc. Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 76. Changchun High-Tech Industry Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 77. Sino Biopharmaceutical Limited Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 78. Bio-Thera Solutions Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 79. 3SBio Inc. Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 80. CARsgen Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 81. Innovent Biologics Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 82. Qilu Pharmaceutical Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 83. Boehringer Ingelheim Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 84. BeiGene Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 85. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 86. Alphamab Oncology Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 87. Shanghai Henlius Biotech Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 88. Ionis Pharmaceuticals Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 89. Gan & Lee Pharmaceuticals Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 90. Anhui Anke Biotechnology Revenue Growth Rate in Biologics for Immune Diseases and Inflammation Business (2020-2025)

Figure 91. Bottom-up and Top-down Approaches for This Report

Figure 92. Data Triangulation

Figure 93. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Biologics for Immune Diseases and Inflammation Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-7K20253

Global Biologics for Immune Diseases and Inflammation Market Research Report 2025

FEATURED COMPANIES

Biologics for Immune Diseases and Inflammation Market Size

Biologics for Immune Diseases and Inflammation Market

Scope of Biologics for Immune Diseases and Inflammation Market Report

Chapter Outline

FAQ for this report

How fast is Biologics for Immune Diseases and Inflammation Market growing?

What is the Biologics for Immune Diseases and Inflammation Market size in 2031?

Who are the main players in the Biologics for Immune Diseases and Inflammation Market report?

What are the Application segmentation covered in the Biologics for Immune Diseases and Inflammation Market report?

What are the Type segmentation covered in the Biologics for Immune Diseases and Inflammation Market report?

FEATURED COMPANIES